BSE · 531146 · Pharmaceuticals
Medicamen Biotech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹44 Cr with net profit ₹3 Cr — a 5.77% net margin, versus 5.43% the period before.
Shareholding
As of 2026-09-30
- Promoter40.46%
- Public55.05%
- FII4.49%
- DII0%
11,680 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.16× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #21 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,73,334 Cr | 79.84 | 9.43 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹50,312 Cr | 43.91 | 4.86 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,233 Cr | 38.1 | 9.55 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹25,889 Cr | 89.83 | 20.09 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹18,228 Cr | 64.1 | 7.03 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹17,960 Cr | 26.99 | 5.33 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹16,307 Cr | 21.78 | 3.93 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,831 Cr | 26.77 | 4.57 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,899 Cr | 50.12 | 5.78 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,099 Cr | 48.26 | 6.53 | 12.36% | 18.59% |
| Medicamen Biotech Ltd.(this company) | ₹358 Cr | 33.08 | 1.22 | 3.5% | 5.35% |
AI analysis
AI-generated · google/gemini-2.5-flashMedicamen Biotech Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 335 Cr. The company reported a profit margin of 5.5% and a dividend yield of 40%. The debt-to-equity ratio stands at 0.15.
Positives
- +The company has a high dividend yield of 40%.
- +The return on equity (ROE) is significantly high at 349.89%.
- +The debt-to-equity ratio is low at 0.15.
- +There is no promoter share pledge recorded.
Negatives
- −Revenue growth for the full year was negative at -9.35%.
- −The company is currently under LT-ASM, indicating regulatory surveillance.
- −The Return on Capital Employed (ROCE) is relatively low at 4.7882%.
- −Promoter holding decreased from 40.4569% in the current period to 34.7% in Mar 2017.
- −No annual revenue or profit figures were provided for the most recent financial year.
Financial Performance
The company’s revenue growth was -9.35%. Quarterly revenue in March 2026 was Rs 60.65 Cr with a net profit of Rs 3.86 Cr. In December 2025, revenue was Rs 46.91 Cr with a net profit of Rs 2.19 Cr. Net profit in March 2025 was Rs 2.42 Cr on revenue of Rs 29.61 Cr.
Profitability & Returns
Medicamen Biotech Ltd. has a profit margin of 5.5%. The return on equity (ROE) is 349.89%, while the return on capital employed (ROCE) is 4.7882%. The earnings per share (EPS) is Rs 7.11.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.15. The book value per share is Rs 203.17. No figures for total assets or liabilities were provided.
Ownership & Pledges
As of June 30, 2026, promoter holding was 40.4569%. Public shareholding was 59.069%, with DIIs holding 0.4032% and FIIs holding 0.0709%. Total institutional holding was 0.4741%. There is no promoter share pledge recorded.
Regulatory & Surveillance
Medicamen Biotech Ltd. is currently under LT-ASM (Long Term Additional Surveillance Measure) · ASM 1, which indicates increased regulatory monitoring.
Data as of — price: 2026-10-28 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.